Entering text into the input field will update the search result below

ARIAD's Iclusig delivers long-term therapeutic benefit in blood cancer patients

  • Follow up from a Phase 2 study assessing ARIAD Pharmaceuticals' (ARIA -1.8%) Iclusig (ponatinib) in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) shows that Iclusig continues to demonstrate anti-leukemic activity for an extended period, specifically a median of 3.5 years for chronic phase CML and a median of 2.9 years for all patients in the trial.
  • An estimated 83% of chronic phase CML patients who achieved a major cytogenic response (MCyR) have maintained their status at three years as well as 95% of those who underwent ponatinib dose reductions.
  • The data were presented at the 20th Congress of the European Hematology Association in Vienna, Austria.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ARIA--
ARIAD Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.